Novo Prepares For Fiercer Fight

Danish pharma giant Novo Nordisk’s recent launch of Ozempic in India alongside a 37% price cut on Wegovy points out at more than a market entry. It reflects a strategic recalibration as semaglutide approaches the latter half of its patent life globally and competitive intensity in obesity care accelerates. With rivals scaling up and next-generation therapies on the horizon, Novo is shaping its India strategy around broader metabolic health outcomes, access expansion and local partnerships. Emil Kongshøj Larsen, Executive Vice President (EVP) for International Operations, Novo Nordisk told Business Today that India will be central to company's growth agenda, with parallel efforts to widen patient reach and defend its GLP-1 franchise as competition intensifies.